Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
Adverse effects
[50] RCT 4-armed trial	129 people	Fatigue 4/32 (13%) with abecarnil (3–9 mg/day) 0/28 (0%) with placebo	Significance not assessed
[50] RCT 4-armed trial	129 people	Equilibrium loss 2/32 (6%) with abecarnil (3–9 mg/day) 0/28 (0%) with placebo	Significance not assessed
[50] RCT 4-armed trial	129 people	Drowsiness 10/32 (31%) with abecarnil (3–9 mg/day) 4/28 (14%) with placebo	Significance not assessed
[50] RCT 4-armed trial	129 people	Proportion of people experiencing at least 1 adverse effect 62% with abecarnil (15–30 mg/day) 51% with abecarnil (7.5–15 mg/day) 22% with abecarnil (3–9 mg/day) 21% with placebo Absolute numbers not reported	Significance not assessed
[50] RCT 4-armed trial	129 people 12/34 (35%) people	Proportion of people who withdrew from treatment 12/34 (35%) with abecarnil (15–30 mg/day) 4/35 (11%) with abecarnil (7.5–15 mg/day) 1/32 (3%) with abecarnil (3–9 mg/day) 2/28 (7%) with placebo	Significance not assessed